A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II

Bibliography

• Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992;23:33-4
   PubMedGoogle Scholar
• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218(4):223-36
   PubMed Web of Science ®Google Scholar
• de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30(6):452-70
   PubMed Web of Science ®Google Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother 2010;11(7):1135-46
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Current and future treatments for Behcet’s uveitis: road to remission. Int Ophthalmol 2013;34(2):365-81
   PubMedGoogle Scholar
• Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 2009;26(5):1236-60
   PubMed Web of Science ®Google Scholar
• Willermain F, Rosenbaum JT, Bodaghi B, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res 2012;31(2):182-94
   PubMed Web of Science ®Google Scholar
• Siddique SS, Shah R, Suelves AM, Foster CS. Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs 2011;20(11):1497-515
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23(6):617-37
   PubMed Web of Science ®Google Scholar
• Dick AD, McMenamin PG, Korner H, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996;26(5):1018-25
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch ophthalmol 2004;122(6):845-51
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005;44(8):1008-11
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch ophthalmol 2003;121(4):437-40
   PubMed Web of Science ®Google Scholar
• Saeed MU, Raza SH, Goyal S, et al. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol 2014;29(1):1-3
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113(12):2317-23
   PubMed Web of Science ®Google Scholar
• Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53(1):18-23
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumore necrosis factor biologic agents in patients with ocular inflammatory diseases. Ophthalmology 2014;121(3):785-96
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr eye Res 2010;35(8):751-6
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm 2012;20(1):44-8
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39(2):233-9
   PubMed Web of Science ®Google Scholar
• Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm 2013;21(6):468-74
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M; Ocular Behcet’s Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012;130(5):592-8
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet’s disease. Ocul Immunol Inflamm 2012;20(3):198-202
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40(1):74-9
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113(5):860-4. e2
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 2012;28(6):628-31
   PubMed Web of Science ®Google Scholar
• Wu L, Arevalo JF, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol 2012;32(3):235-43
   PubMedGoogle Scholar
• Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30(1):71-80
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146(6):802-12. e1
   PubMed Web of Science ®Google Scholar
• Kawazoe Y, Sugita S, Yamada Y, et al. Psoriasis triggered by infliximab in a patient with Behcet’s disease. Jpn J Ophthalmol 2013;57(1):95-7
   PubMed Web of Science ®Google Scholar
• Kayama T, Otsuka A, Miyachi Y, Kabashima K. Improvement of anti-TNFalpha antibody-induced pustular psoriasis by azathioprine. Eur J Dermatol 2012;22(4):565-6
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24(3):351-61
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet’s disease: experience in 19 patients. Rheumatology 2012;51(10):1825-31
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behcet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011;29(4 Suppl 67):S54-7
   PubMed Web of Science ®Google Scholar
• Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int 2011;31(2):243-5
   PubMed Web of Science ®Google Scholar
• Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010;117(8):1612-16
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with Golimumab for severe uveitis. Ocul Immunol Inflamm 2013;22(2):90-5
   PubMed Web of Science ®Google Scholar
• Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol 2013;42(4):392-5
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 2013;31(2):320-1
   PubMed Web of Science ®Google Scholar
• Mesquida M, Victoria Hernandez M, Llorenc V, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2013;21(2):160-2
   PubMed Web of Science ®Google Scholar
• William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2012;2(4):231-3
   PubMedGoogle Scholar
• Cordero-Coma M, Salom D, Diaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology 2011;118(9):1892 e3-4
   PubMedGoogle Scholar
• Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn’s disease. Ann Pharmacother 2010;44(2):333-42
   PubMed Web of Science ®Google Scholar
• Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 1997;40(3):397-409
   PubMed Web of Science ®Google Scholar
• Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13(2):559-75
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-71
   PubMed Web of Science ®Google Scholar
• Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001;108(6):895-903
   PubMed Web of Science ®Google Scholar
• Pollard L, Choy E. Rheumatoid arthritis: non-tumor necrosis factor targets. Curr Opin Rheumatol 2005;17(3):242-6
   PubMed Web of Science ®Google Scholar
• Silver PB, Hathcock KS, Chan CC, et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000;165(9):5041-7
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372(9636):383-91
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 2008;35(9):1897-8
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010;62(6):821-5
   PubMed Web of Science ®Google Scholar
• Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res 2011;63(2):307-8. author reply 8
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249(2):297-300
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. ClinicalTrials.gov results for "uveitis". 2014. Available from: http://clinicaltrials.gov/ct2/ results?term=uveitis
   Google Scholar
• Atzeni F, Benucci M, Salli S, et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013;12(5):575-9
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013;12(7):703-8
   PubMed Web of Science ®Google Scholar
• Epis OM, Giacomelli L, Deidda S, Bruschi E. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2013;12(8):839-41
   PubMed Web of Science ®Google Scholar
• Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008;28(3):205-15
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet’s disease with rituximab. Mod Rheumatol 2008;18(3):306-8
   PubMed Web of Science ®Google Scholar
• Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Semin Ophthalmol 2011;26(4-5):295-303
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13(3):246-52
   PubMed Web of Science ®Google Scholar
• Rituximab, prescribing information. 2014. Available from: http://www.gene.com/download/pdf/rituxan_prescribing.pdf
   Google Scholar
• Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007;39(3):184-6
   PubMed Web of Science ®Google Scholar
• Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30(9):1163-72
   PubMed Web of Science ®Google Scholar
• Narvaez J, Diaz-Torne C, Juanola X, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68(4):607-8
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011;50(8):1390-4
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology 2011;118(1):223-4
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11(1):35-9
   PubMed Web of Science ®Google Scholar
• Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol 2005;117(3):207-13
   PubMed Web of Science ®Google Scholar
• Garbett ND, Munro CS, Cole PJ. Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with sandoglobulin. Clin Exp Immunol 1989;76(1):8-12
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126(9):721-30
   PubMed Web of Science ®Google Scholar
• Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96(6):1057-61
   PubMed Web of Science ®Google Scholar
• Jacobs P, Wood L, Novitzky N. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. Am J Med 1994;97(1):55-9
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329(27):1993-2000
   PubMed Web of Science ®Google Scholar
• Achiron A, Barak Y, Goren M, et al. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol 1996;104(Suppl 1):67-70
   PubMed Web of Science ®Google Scholar
• Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta neurol Scand 1991;84(2):81-4
   PubMed Web of Science ®Google Scholar
• Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999;106(11):2136-43
   PubMed Web of Science ®Google Scholar
• Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12(2):163-8
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994;97(Suppl 1):31-8
   PubMedGoogle Scholar
• Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004;111(7):1380-2
   PubMed Web of Science ®Google Scholar
• Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992;35(10):1126-33
   PubMed Web of Science ®Google Scholar
• Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005;6(5):327-42
   PubMed Web of Science ®Google Scholar
• Cousens LP, Tassone R, Mazer BD, et al. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013;12(3):436-43
   PubMed Web of Science ®Google Scholar
• Djoumerska-Alexieva I, Pashova S, Vassilev T, Pashov A. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 2013;12(6):653-6
   PubMed Web of Science ®Google Scholar
• Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012;11(11):792-4
   PubMed Web of Science ®Google Scholar
• Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 2011;10(12):809-10
   PubMed Web of Science ®Google Scholar
• Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104(Suppl 1):3-9
   PubMedGoogle Scholar
• Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn’s disease. Autoimmun Rev 2012;12(2):275-80
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Marson P, Svaluto-Moreolo G, et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev 2013;12(7):768-73
   PubMed Web of Science ®Google Scholar
• Obrador E, Peinado E, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use prevent endotoxin-induced uveitis in rats. Ophthalmic Res 1999;31(1):59-67
   PubMed Web of Science ®Google Scholar
• Saoudi A, Hurez V, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993;5(12):1559-67
   PubMed Web of Science ®Google Scholar
• Blum M, Andrassy K, Adler D, et al. Early experience with intravenous immunoglobulin treatment in Wegener’s granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997;235(9):599-602
   PubMed Web of Science ®Google Scholar
• Frohman LP, Cook SD, Bielory L. Dysgammaglobulinemia in steroid-dependent optic neuritis: response to gammaglobulin treatment. J Clin neuroophthalmol 1991;11(4):241-5
   PubMedGoogle Scholar
• Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999;127(5):545-9
   PubMed Web of Science ®Google Scholar
• Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcet’s disease. Br J Ophthalmol 2001;85(11):1287-8
   PubMed Web of Science ®Google Scholar
• LeHoang P, Cassoux N, George F, et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000;8(1):49-57
   PubMed Web of Science ®Google Scholar
• Cassoux N, Goichot-Bonnat L, Karmochkine M, et al. [Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis]. J Fr Ophtalmol 2002;25(1):23-30
   PubMed Web of Science ®Google Scholar
• Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 2006;14(6):367-74
   PubMed Web of Science ®Google Scholar
• Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999;21(3):171-85
   PubMed Web of Science ®Google Scholar
• Yao Y, Liu Z, Jallal B, et al. Type I interferons in Sjogren’s syndrome. Autoimmun Rev 2013;12(5):558-66
   PubMed Web of Science ®Google Scholar
• Saadoun D, Bodaghi B, Bienvenu B, et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013;12(7):774-83
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behcet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278(4):335-6
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138(4):467-71
   PubMed Web of Science ®Google Scholar
• Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol 2012;51:90-7
   PubMedGoogle Scholar
• Hazirolan D, Stubiger N, Pleyer U. Light on the horizont: biologicals in Behcet uveitis. Acta Ophthalmol 2013;91(4):297-306
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein A, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet’s disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 2003;528:521-3
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology 2010;117(7):1430-5
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum 2010;62(9):2796-805
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005;89(10):1254-7
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 2013;156(3):478-86. e1
   PubMed Web of Science ®Google Scholar
• Planck SR, Woods A, Clowers JS, et al. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis 2012;71(5):753-60
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007;91(2):263-4
   PubMed Web of Science ®Google Scholar
• Terrada C, Neven B, Boddaert N, et al. Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophthalmic Inflamm Infect 2011;1(3):133-6
   Google Scholar
• Botsios C, Sfriso P, Furlan A, et al. Resistant Behcet disease responsive to anakinra. Ann Intern Med 2008;149(4):284-6
   PubMed Web of Science ®Google Scholar
• Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet’s disease. Rheumatol Int 2005;25(1):1-5
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70(5):747-54
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 2009;48(4):347-54
   PubMed Web of Science ®Google Scholar
• Caspi RR, Roberge FG, McAllister CG, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 1986;136(3):928-33
   PubMed Web of Science ®Google Scholar
• Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6(2):111-20
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Raber J, Chan CC, et al. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997;158(1):452-8
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338(3):161-5
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999;96(13):7462-6
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112(5):764-70
   PubMed Web of Science ®Google Scholar
• Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110(4):786-9
   PubMed Web of Science ®Google Scholar
• Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009;148(5):696-703. e1
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008;31(2):91-7
   PubMed Web of Science ®Google Scholar
• Li Z, Lim WK, Mahesh SP, et al. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 2005;174(9):5187-91
   PubMed Web of Science ®Google Scholar
• Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126(2):186-91
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm 2007;15(2):63-70
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985;1(4):369-82
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001;131(5):679
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4(4):386-91
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-50
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004;126(4):989-96. discussion 47
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(6):1761-9
   PubMed Web of Science ®Google Scholar
• Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15(5):581-6
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52(3):818-25
   PubMed Web of Science ®Google Scholar
• Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011;52(6):3264-71
   PubMed Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011;19(5):382-3
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012;22(2):298-302
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012;39(6):1294-5
   PubMed Web of Science ®Google Scholar
• Wofford J, Menter A. Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2014;10(2):189-202
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 2013;72(4):626-7
   PubMed Web of Science ®Google Scholar
• Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63(12):1229-43. discussion 45-6
   PubMed Web of Science ®Google Scholar
• Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84(1):107-9
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology 2003;42(12):1539-44
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120(4):777-87
   PubMed Web of Science ®Google Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology 2014;121(1):365-76
   PubMed Web of Science ®Google Scholar
• Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30(6):475-7
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012;71(4):563-6
   PubMed Web of Science ®Google Scholar
• He Y, Jia SB, Zhang W, Shi JM. New options for uveitis treatment. Int J Ophthalmol 2013;6(5):702-7
   PubMed Web of Science ®Google Scholar
• Tian L, Yang P, Lei B, et al. AAV2-mediated subretinal gene transfer of hIFN-alpha attenuates experimental autoimmune uveoretinitis in mice. PLoS One 2011;6(5):e19542
   PubMed Web of Science ®Google Scholar
• Trittibach P, Barker SE, Broderick CA, et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther 2008;15(22):1478-88
   PubMed Web of Science ®Google Scholar
• Tian L, Lei B, Shao J, et al. AAV2-mediated combined subretinal delivery of IFN-alpha and IL-4 reduces the severity of experimental autoimmune uveoretinitis. PLoS One 2012;7(6):e37995
   PubMed Web of Science ®Google Scholar
• Shao J, Tian L, Lei B, et al. AAV2-mediated subretinal gene transfer of mIL-27p28 attenuates experimental autoimmune uveoretinitis in mice. PLoS One 2012;7(5):e37773
   PubMedGoogle Scholar
• Choi B, Hwang Y, Kwon HJ, et al. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008;52(2):87-97
   PubMed Web of Science ®Google Scholar
• Hou Y, Xing L, Fu S, et al. Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol 2009;247(6):755-65
   PubMed Web of Science ®Google Scholar
• Iwata D, Kitamura M, Kitaichi N, et al. Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA. Exp Eye Res 2010;90(1):41-8
   PubMed Web of Science ®Google Scholar
• Cho WG, Albuquerque RJ, Kleinman ME, et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci USA 2009;106(17):7137-42
   PubMed Web of Science ®Google Scholar
• Canavan JB, Afzali B, Scotta C, et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012;119(8):e57-66
   PubMed Web of Science ®Google Scholar